西洛他唑对2型糖尿病患者尿白蛋白排泄率的影响

目的探讨西洛他唑治疗2型糖尿病早期肾病的临床疗效。方法将60例血压正常伴微量白蛋白尿的2型糖尿病患者，随机分为两组：治疗组30例，予口服西洛他唑片（50mg，2次/d）；对照组30例，予口服安慰剂维生素B。（10mg，2次/d），两组均治疗3个月。观察患者治疗前后尿白蛋白排泄率（UAEK）的变化。结果治疗组较治前，UAEK明显下降（P〈0．01），下降幅度达51．6％，肝肾功能均正常，约3％病人仅有轻微头痛反应。对照组治疗前后UAER无明显变化（均P〉0．05）。结论西洛他唑能显著降低糖尿病患者尿白蛋白的排泄，对糖尿病早期肾病具有治疗作用，且安全性好。

Effect of Cilostazol on urinary albumin excretion rate in type 2 diabetic patients

[Objective] To evaluate the efficacy of Cilostazol in treating incipient diabetic nephropathy in type 2 diabetic patients. [Methods] Sixty cases of normotensive type 2 diabetes with microalbuminuria were randomized into two groups, 30 cases in each. The Cilostazol-treated group was orally given Cilostazol (50 mg, bid) for 3 months. Whereas, the control group received vitamin B1 (10 mg, bid) also for 3 months. Before and after the study, urinary albumin excretion rate (UAER) was investigated. [Results] In Cilostazol-treated group UAER was markedly decreased (P <0.01) by 51.6%. Renal and liver function tests were kept normal. Only 3% of the patients developed mild headache during Cilostazol treatment. By contrast, UAER did not show any significant change in control group (P >0.05). [Conclusion] Cilostazol decreases urine albumin excretion efficiently in the diabetic patients with incipient diabetic nephropathy. Cilostazol is safe and well tolerated.